Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NNC6019-0001 in Transthyretin Amyloid Cardiomyopathy (ATTR CM)
NCT06260709Phase 2Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Feb 2024
- Primary completion
- Feb 2028
- Modality
- Monoclonal Antibodies
- Countries
- 10
01
Overview
A Phase 2 trial of coramitug in transthyretin amyloid cardiomyopathy (ATTR-CM), sponsored by Novo Nordisk. Started Feb 2024; status: active, not recruiting.
02
Drugs
coramitug
03
Conditions
transthyretin amyloid cardiomyopathy (ATTR-CM)
Beyond the preview
Go deeper on NCT06260709.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06260709.